Our data indicate that deletion of ChREBP delays insulin-induced hepatocarcinogenesis, suggesting a combined oncogenic and lipogenic function of ChREBP along with AKT/mTOR-mediated proliferation of hepatocytes and induction of HCC. The gene discussed is AKT1; the disease is hepatocellular carcinoma.